Loading
Dermatological and Skeletal Disorders / Alzheimer's Disease Research and Treatments · Journal article
Orphanet Journal of Rare Diseases · August 31, 2026
A consensus or society position rather than new primary data.
This is a narrative literature review integrating current knowledge on epidemiology, diagnostic strategies, and disease-modifying therapies for hereditary transthyretin amyloidosis with polyneuropathy. The review recommends early genetic testing, minimally invasive diagnosis, and stage-adapted disease-modifying therapy within multidisciplinary care, but does not present primary trial data or quantified comparative efficacy.
Narrative literature review. Patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN); a progressive, fatal multisystem disorder with genotypic and geographic heterogeneity..
Region-specific variant distributions identified (e.g., p.Val50Met, p.Ala117Ser). Diagnostic paradigm shifted toward early genetic testing and minimally invasive biopsies with emerging serum biomarkers including neurofilament light chain (NfL). Gene-silencing agents (siRNAs and ASOs) and TTR stabilizers demonstrated robust efficacy in halting neuropathy progression.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should prioritize early genetic screening and minimally invasive diagnostic approaches for suspected ATTRv-PN to reduce diagnostic delay. Stage-adapted initiation of disease-modifying therapies within a multidisciplinary framework is recommended for optimizing long-term outcomes, though specific comparative efficacy and patient selection criteria require appraisal of underlying trials.
A narrative review synthesizing epidemiological, diagnostic, and therapeutic literature on a rare genetic disorder, presenting clinical consensus and recommendations rather than primary evidence from a trial or analysis.
As stated by the source record.
Clinicians should prioritize early genetic screening and minimally invasive diagnostic approaches for suspected ATTRv-PN to reduce diagnostic delay. Stage-adapted initiation of disease-modifying therapies within a multidisciplinary framework is recommended for optimizing long-term outcomes, though specific comparative efficacy and patient selection criteria require appraisal of underlying trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Background Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a progressive, fatal multisystem disorder characterized by significant genotypic and geographic heterogeneity. Despite recent therapeutic breakthroughs, overlapping clinical features frequently lead to misdiagnosis and delayed intervention. Methods A comprehensive narrative review of the literature was conducted to synthesize recent advancements in the epidemiology, diagnostic workflows, and therapeutic landscape of ATTRv-PN, with an emphasis on clinical translation and multidisciplinary management. Results The epidemiological profile of ATTRv-PN highlights region-specific variant distributions (e.g., p.Val50Met, p.Ala117Ser). The diagnostic paradigm has shifted towards prioritizing early genetic testing and minimally invasive biopsies, complemented by emerging serum biomarkers like neurofilament light chain (NfL) and advanced neuroimaging. Therapeutically, the landscape has been transformed by disease-modifying therapies (DMTs). Gene-silencing agents (siRNAs and ASOs) and TTR stabilizers have demonstrated robust efficacy in halting neuropathy progression. Furthermore, novel modalities, including amyloid-depleting monoclonal antibodies and in vivo CRISPR/Cas9 gene-editing therapies, show unprecedented promise in ongoing clinical trials. Conclusions ATTRv-PN has entered an era of precision medicine. Overcoming diagnostic delays through “red-flag” recognition and routine genetic screening is imperative. Early, stage-adapted initiation of DMTs within a multidisciplinary care framework is crucial for optimizing long-term patient outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.